Skip to main content
. Author manuscript; available in PMC: 2015 Jul 15.
Published in final edited form as: Clin Cancer Res. 2014 May 16;20(14):3730–3741. doi: 10.1158/1078-0432.CCR-13-3446

Figure 3. Veliparib sensitizes GBM12 derivative TMZ-resistant xenograft lines in vitro.

Figure 3

A, B) Cytotoxicity assay: the sensitive GBM12 and derivative TMZ resistant sub-lines, GBM12TMZ-mgmtLow and GBM12TMZ-mgmtHigh were analyzed for neurosphere growth following treatment with graded concentrations of veliparib and/or TMZ, A) the relative neurosphere counts for the indicated treatments are graphed as the mean ± SEM from 3 independent experiments. B) The calculated IC50 for TMZ at different concentrations of veliparib are plotted as the mean ± SD from 3 independent experiments. C) DNA damage signaling: GBM12 and derivative sub-lines were treated for 24 hours with the indicated doses of veliparib and/or TMZ and then processed for immunoblotting with the indicated antibodies. D) Cells were analyzed for γH2AX foci as in Figure 2 after drug treatment for 24 hours. Results are plotted as the mean ± SEM from a minimum of 3 independent experiments. * indicates a p-value ≤ 0.05 and NS a p-value > 0.05 and MW, molecular weight.